Corporate Banner
Satellite Banner
Spectroscopy
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Conformetrix and AstraZeneca Sign Collaborative Agreement

Published: Thursday, April 26, 2012
Last Updated: Thursday, April 26, 2012
Bookmark and Share
First collaborative deal for Conformetrix.

Conformetrix Ltd and AstraZeneca have announced that they have signed a research collaboration agreement under which Conformetrix's proprietary NMR-based technology will be applied across AstraZeneca's pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

Conformetrix's technology determines accurate three-dimensional structures - or conformations - of drug molecules in their bioactive states.

This is achieved without the need for traditional structural information regarding the protein target of each drug and provides researchers with valuable information on how development-stage compounds are likely to interact with their targets.

This new information should improve the efficiency and quality of the lead identification, lead optimization and candidate selection stages of drug discovery programmes.

Under the terms of the two-year collaboration, the technology will also be used to determine the bioactive conformations of naturally occurring ligands as templates for drug library enhancement and hit identification.

Commenting on today's news, Conformetrix's CEO, Dr Sam Williams, said, 'Conformetrix is delighted that its first collaborative deal is with AstraZeneca, a company with a strong reputation in innovative science-led R&D. We believe that this deal provides important validation of our technology, which improves the quality and efficiency of drug discovery, reducing the number of molecules needed to find a drug and enhancing the likelihood of clinical success. The Conformetrix team is looking forward to working with our new partner on this exciting programme.'

Mike Snowden, Vice President and Head of Discovery Sciences, AstraZeneca, said: "We are excited to be working with Conformetrix. We believe their technology will provide a powerful addition to our hit identification and lead optimization approaches, supporting our strategic objectives to improve the quality and choice of candidate compounds for our early pipeline."

In addition to an undisclosed upfront payment, Conformetrix will receive research funding and be eligible for milestones as certain targets are met. The discovery programme will be managed by a joint AstraZeneca-Conformetrix research team.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Kwansei Gakuin University in Hyogo, Japan, Uses Raman Microscopy
Raman Microscopy study crystallographic defects in silicon carbide wafers.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
X-ray Laser Experiment Could Help in Designing Drugs for Brain Disorders
Scientists found that when two protein structures in the brain join up, they act as an amplifier for a slight increase in calcium concentration, triggering a gunshot-like release of neurotransmitters from one neuron to another.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Major Innovation in Molecular Imaging Delivers Spatial and Spectral Info Simultaneously
Berkeley Lab scientist invents technique to combine spectroscopy with super-resolution microscopy, enabling new ways to examine cell structures and study diseases.
Helicobacter Pylori's Secret Weapon
Finding the molecular interactions that make this pathogen so successful in such a harsh environment has, until now, proved elusive.
Unprecedented Insights Into the Reactions Powering Fuel Cells
Nanotech-enabled chip developed at UCLA can analyze chemical reactions more accurately than large machines
Ultrafast Laser Pulses for Spectroscopy and Biomedical Applications
Graphene Flagship researchers have developed an optical fibre laser that emits pulses with durations equivalent to just a few wavelengths of the light used. This fastest ever laser based on graphene will be ideal for use in ultrafast spectroscopy, and in surgical lasers that avoid heat damage to living tissue.
Device May Detect Urinary Tract Infections Faster
A Lab-on-a-Disc platform developed by a German and Irish team of researchers dramatically cut the time to detect bacterial species that cause urinary tract infections -- a major cause of sepsis.
New Hybrid Microscope Offers Unparalleled Capabilities
A microscope being developed at the Department of Energy’s Oak Ridge National Laboratory will allow scientists studying biological and synthetic materials to simultaneously observe chemical and physical properties on and beneath the surface.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!